BARINTHUS BIOTHERAPEUTICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.27 USD | +2.71% |
|
+10.73% | -38.48% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 88.35M |
|---|---|---|---|---|---|
| Net income 2024 * | -100M | Net income 2025 * | -124M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 238M | Net cash position 2025 * | 92.65M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.05
x | P/E ratio 2025 * |
-0.93
x | Employees | 130 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 47.98% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +2.71% | ||
| 1 week | +10.73% | ||
| Current month | +10.73% | ||
| 1 month | -31.21% | ||
| 3 months | -14.66% | ||
| 6 months | -44.63% | ||
| Current year | -38.48% |
1 week
2.08
2.40
1 month
1.823.51
Current year
1.824.16
1 year
1.645.10
3 years
1.6417.99
5 years
1.6417.99
10 years
1.6417.99
| Managers | Title | Age | Since |
|---|---|---|---|
William Enright
CEO | Chief Executive Officer | 61 | 19-07-31 |
Gemma Brown
DFI | Director of Finance/CFO | 34 | 21-08-31 |
Nadège Pelletier
CTO | Chief Tech/Sci/R&D Officer | 46 | 23-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Karen Dawes
BRD | Director/Board Member | 72 | 21-02-28 |
William Enright
CEO | Chief Executive Officer | 61 | 19-07-31 |
Anne Phillips
BRD | Director/Board Member | 70 | 21-02-20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-07 | 2.27 | +2.71% | 2,347 |
| 24-05-06 | 2.21 | +1.38% | 7,982 |
| 24-05-03 | 2.18 | +1.63% | 5,307 |
| 24-05-02 | 2.145 | -2.50% | 3,060 |
| 24-05-01 | 2.2 | +7.32% | 17,755 |
Delayed Quote Nasdaq, May 07, 2024 at 04:30 pm EDT
More quotes
Barinthus Biotherapeutics plc, formerly Vaccitech plc, is a clinical-stage biopharmaceutical company. It is focused on developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. Its four platform technologies include ChAdOx, MVA, SNAP-TI, and SNAP-CI. It is advancing a pipeline of five product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer, and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.27
USD
Average target price
7.4
USD
Spread / Average Target
+225.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -38.48% | 88.35M | |
| +21.74% | 46.4B | |
| -0.97% | 41.75B | |
| +49.22% | 41.37B | |
| -3.52% | 29.71B | |
| +11.12% | 26.01B | |
| -19.37% | 19.52B | |
| +31.18% | 12.43B | |
| -0.04% | 12.13B | |
| +0.39% | 12.18B |
- Stock Market
- Equities
- BRNS Stock